Ninety Minutes of Apnea at a Freestanding Surgery Center

Build the differential in four buckets:

• Central drive: residual propofol or opioid, hypercapnia, hypothermia, hypoglycemia, neurologic event. Arguments against: temperature 36.3 °C, normal gas exchange, stable hemodynamics, and complete absence of twitches rather than weak twitches. Residual opioid would blunt but not abolish the twitch response.
• Neuromuscular junction: atypical pseudocholinesterase, phase II block, drug interaction. No magnesium, aminoglycoside, or local anesthetic exposure, and only a single 1.5 mg/kg dose was given, so dose-related phase II block is unlikely.
• Mechanical: LMA malposition, obstruction, ventilator failure - excluded by easy ventilation with a normal capnogram.
• Metabolic: hypokalemia, hypocalcemia, hypermagnesemia - all normal.

The two bedside discriminators are train-of-four behavior and response to a small neostigmine dose. No fade with tetanic or double-burst stimulation favors a phase I block from a cholinesterase variant; fade with post-tetanic potentiation favors phase II. Neostigmine should not improve a phase I block. Activity of 240 U/L plus the sibling history makes a variant likely, but low activity alone also occurs with liver disease and organophosphate exposure, so dibucaine and fluoride numbers or genotyping are needed to confirm.

Neostigmine inhibits acetylcholinesterase, which increases acetylcholine at the endplate. In a phase I depolarizing block the endplate is already depolarized by agonist; adding more agonist does not restore the membrane potential and may prolong the block. There is no enzyme for neostigmine to inhibit in plasma - the deficient enzyme is butyrylcholinesterase, not the acetylcholinesterase at the junction - so the drug cannot fix the actual defect. Giving it also risks bradycardia and does nothing for a patient who is already apneic.

Management:

• Keep the patient sedated (propofol infusion) and mechanically ventilated; do not extubate until sustained twitches, a train-of-four ratio above 0.9, and adequate spontaneous ventilation with a normal ETCO2 are present.
• Monitor train-of-four every 15–20 minutes to track recovery; the block typically resolves over 2–8 hours depending on genotype.
• Avoid further succinylcholine, mivacurium (also metabolized by plasma cholinesterase), and ester local anesthetics such as procaine and chloroprocaine.
• Fresh frozen plasma provides exogenous enzyme and has been used in life-threatening cases, but it is rarely required for a single dose and carries transfusion risk; reserve it for failure to recover after many hours.
• Document the event and give the patient a medical alert card.

The patient cannot be discharged and cannot be managed on a routine ambulatory pathway, so the decision is a transfer decision, not an extubation decision.

• Call the medical director and the receiving hospital immediately; arrange ambulance transfer to a facility with an ICU or at least overnight ventilatory capability. The anesthesiologist accompanies the patient; a PACU nurse and anesthesia technician stay until transfer.
• Continue sedation and ventilation during transport with a transport ventilator, capnography, and pulse oximetry; keep the laryngeal mask or exchange for an endotracheal tube if transport conditions or duration make the supraglottic airway unreliable.
• Notify the surgeon and the family, explain what is known and what is not, and avoid promising a timeline.
• Do not present this as a routine prolonged wake-up: the sibling history and low activity suggest an inherited variant, which has implications for future anesthetics and for relatives. Refer for genetic counseling and advise screening of first-degree relatives.
• Chart the objective timeline, doses, train-of-four findings, and the conversations held.